Adam’s Take

Insights and opinions from senior biotech writer Adam Feuerstein

Adam's Take

The biotech M&A spotlight shifts to Biogen, with some clear candidates to acquire

By Adam Feuerstein

Scott Gottlieb
Adam's Take

An open letter to Dr. Scott Gottlieb on FDA transparency

By Adam Feuerstein

JP Morgan 2017
Adam's Take

We went to #JPM18 with burning questions about biotechs. We got some answers

By Adam Feuerstein

JP Morgan 2017
Adam's Take

It’s a pivotal moment for Dermira and its acne medication. What are its chances?

By Adam Feuerstein

JP Morgan 2017
Adam's Take

JPM is like a biotech dating game, just ask these questions before hooking up

By Adam Feuerstein

Knee Xray
Adam's Take

With an arthritis drug no better than common saline, Ampio Pharma’s shot at FDA approval is dim

By Adam Feuerstein

Cranky toddler
Adam's Take

Biotech stocks in 2017 were a lot like toddlers. Here’s why

By Adam Feuerstein

storm clouds
Adam's Take

For biotech analysts, the outlook for 2018 is dark and stormy

By Adam Feuerstein

Good/Bad CEO 2017
Adam's Take

Maraganore runs away with best biopharma CEO award; Soon-Shiong wins prize for worst

By Adam Feuerstein

Worst Biotech CEOs 2017
Adam's Take

And now, your nominees for worst biopharma CEO of 2017. Let the voting begin!

By Adam Feuerstein

ASH 2017 story card
Adam's Take

ASH winners and losers: Hemophilia therapies show promise, Syros stumbles

By Adam Feuerstein

Best Biotech CEOs 2017
Adam's Take

Introducing the nominees for best biopharma CEO of 2017. Vote for your favorite!

By Adam Feuerstein

Adam's Take

Biotech stocks, on a strong run all year, are taking a breather

By Adam Feuerstein

Adam's Take

Here’s why investors in Geron, Puma Bio, Intrexon, and Ziopharm should worry

By Adam Feuerstein

Adam's Take

His stock has tanked, his drugs have failed, and CytRx chief Steve Kriegsman knows who’s at fault: Me

By Adam Feuerstein

Harvoni
Business

Gilead’s hepatitis C business is still shrinking and investors are freaking out

By Adam Feuerstein

Celgene
Biotech

Celgene shares plummet on deep cut to long-range financial guidance

By Adam Feuerstein

Adam's Take

The case for approving DBV’s peanut allergy vaccine; Celgene, Trump, and serial drug price hikes

By Adam Feuerstein

Adam's Take

Behold the power of magical thinking: How a tiny lung cancer study sent Spectrum’s stock soaring

By Adam Feuerstein

Adam's Take

Spark Therapeutics’s success is lifting all gene therapy stocks even though risks remain

By Adam Feuerstein

Adam's Take

MannKind raises new cash to prop up a sinking inhaled insulin product

By Adam Feuerstein

Adam's Take

How a whole lot of hype sent Endocyte’s stock soaring for no good reason

By Adam Feuerstein

Adam's Take

Catabasis conjures a stock gain from a failed Duchenne study, assisted by a frothy biotech market

By Adam Feuerstein

Biotech

Zogenix drug cuts seizure rate in severe epilepsy, sending stock skyrocketing

By Adam Feuerstein

Adam's Take

Here’s why Alnylam stock took off like a rocket, stunning (and delighting) investors

By Adam Feuerstein

Biotech

What to watch for when Zogenix and Amicus disclose important clinical trial results

By Adam Feuerstein

Neurons
Business

5 things to know about Sage’s must-win drug trials in postpartum depression

By Adam Feuerstein

Adam's Take

The investor euphoria for Incyte’s experimental cancer drug is hard to rationalize

By Adam Feuerstein

Adam's Take

Cellectis off-the-shelf CAR-T therapy grounded following patient’s toxic death

By Adam Feuerstein

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy